p53: An Attractive Therapeutic Target for Cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Cancer is a major global health challenge, often driven by mutations in cell cycle regulatory genes.
• The tumor suppressor protein p53, crucial for genomic stability, is frequently inactivated in cancers, often due to MDM2 overexpression.
• Targeting the p53-MDM2 interaction is a key therapeutic strategy.

Purpose of the Study:

• To review the therapeutic potential of targeting the p53-MDM2 interaction in cancer.
• To examine the druggability and optimization of small molecule inhibitors of p53-MDM2.
• To categorize and discuss clinical candidates based on their molecular scaffolds.

Main Methods:

• Literature review of scientific publications and clinical trial data.
• Analysis of small molecule inhibitors targeting the p53-MDM2 protein-protein interaction.
• Categorization of inhibitors by chemical scaffold type.

Main Results:

• Several classes of small molecules have demonstrated potent and selective inhibition of p53-MDM2.
• Optimization strategies have improved the efficacy and druggability of these inhibitors.
• Various clinical candidates targeting this pathway are under investigation.

Conclusions:

• Inhibiting the p53-MDM2 interaction represents a viable and promising therapeutic strategy for a broad range of cancers.
• Continued development of p53-MDM2 inhibitors offers significant potential for novel cancer treatments.
• Understanding inhibitor scaffolds is crucial for advancing clinical development.